To confirm the broad applicability of our single-plasmid CRISPR fusion approach, we applied it to three additional cell lines: two intrahepatic, FGFR2-fusion-negative CCA cell lines HUH-28 and CCSW-1, and the immortalized cholangiocyte cell line MMNK-1. This evidence concerns the gene FGFR2 and cholangiocarcinoma.